Folate receptor targeted nanoparticle drug conjugates and uses thereof

US11744897B2 · kind B2 · utility

Assignee

• Elucida Oncology, Inc. · US

Inventors

• Kai Ma · Ithaca, US
• Aranapakam Mudumbai Venkatesan · New York, US
• Feng-Jing Chen · New York, US
• Fei Wu · New Taipei, TW
• Melik Z. Turker · Princeton, US
• Thomas C. Gardinier · Raritan, US
• Geno J. Germano, Jr. · Philadelphia, US
• Gregory P. Adams · Hatboro, US
• Francis Y. Lee · Yardley, US

Key dates

• Filing date: Jul 18, 2022
• Grant date: Sep 5, 2023
• Expiry date: Jul 18, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.